Pfizer stock was trading at $45.34 as of 10:26 AM EDT.
On Monday, Zentalis Pharmaceuticals ( NASDAQ:ZNTL ) announced that it intended to begin the first study for its cancer therapeutic candidate ZN-c3 as part of its partnership with Pfizer ( NYSE:PFE ).
The study is part of a deal between the two companies that have already been made public, along with the New York-based pharmaceutical giant’s $25 million investment in Zentalis.
The BEACON regimen, which combines ZN-c3 with cetuximab and encorafenib to treat patients with metastatic colorectal cancer who have the BRAF V600E mutation, will be launched by the firms (mCRC). Zentalis anticipates beginning patient registration in the first quarter of 2023.
ZNTL rose 3% to $23 in premarket trading on October 24.
Pfizer Stock Analyzed
Pfizer Inc. ( NYSE:PFE ), one of the largest research-based pharmaceutical companies in the world, was one of the first to work on inflammation, oncology, vaccines, and rare disorders. The business has shown that it can create value for its shareholders by growing on its own and making smart purchases. Pfizer is in a good position to keep doing well financially because it has a strong pipeline of potential new drugs and stays focused on ways to c...
Click here to read the full article on PressReach.com .Subscribe to the PressReach RSS feeds:
- Featured News RSS feed
- Investing News RSS feed
- Daily Press Releases RSS feed
- Trading Tips RSS feed
- Investing Videos RSS feed
Follow PressReach on Twitter
Follow PressReach on TikTok
Follow PressReach on Instagram
Subscribe to us on Youtube